Cold Plasma Market - By Pressure (Atmospheric Pressure Cold Plasma, Low-Pressure Cold Plasma), Application (Wound Healing, Cancer Treatment, Dentistry, Blood Coagulation), End-use (Hospital, Dental Clinic, Research and Academic Institution) – Global Forecast, 2023-2032

Cold Plasma Market Size

Cold Plasma Market size was valued at USD 1.8 billion in 2022 and is estimated to account for USD 6.9 billion by 2032. Cold plasma is a state of matter similar to traditional (thermal) plasma but with significantly lower temperatures. Cold plasma efficiently disinfects hospitals, sterilizing surfaces, and equipment without heat damage, reducing HAIs, complications, extended stays, and healthcare costs.
 

According to CDC report, in the U.S., hospital-acquired infections (HAIs) lead to approximately 1.7 million infections and 99,000 deaths each year. Thus, the increasing prevalence of HAIs in healthcare settings is driving the adoption of cold plasma technology.
 

In addition, the versatile applications of cold plasma technology, such as wound healing, surface disinfection, medical equipment sterilization, and dental care, are fueling its demand in the healthcare sector. This demand is driven by the imperative to mitigate infection risks, improve patient safety, and enhance the overall quality of healthcare services.
 

COVID-19 Impact

The COVID-19 pandemic disrupted the cold plasma market, resulting in supply chain disruptions, export bans, and delays in essential product deliveries. Moreover, issues included transportation bottlenecks, reduced manufacturing capacity, and a shortage of healthcare workers. However, as COVID-19 restrictions eased and healthcare services began to recover, the demand for cold plasma in disease treatment is projected to rise, leading to market growth in the subsequent period.
 

Cold Plasma Market Trends

Cold plasma is being explored for its potential in cancer treatment, particularly in oncology which is estimated to reach USD 690.4 billion by 2032. It is used to selectively target and kill cancer cells without harming healthy tissue. For instance, the Jerome Canady Research Institute (JCRI) and US Medical Innovations (USMI) have achieved success in an FDA Phase 1 Clinical Trial by using Canady Helios Cold Plasma (CHCP) alongside tumor resection. This approach selectively eliminates cancer cells at the surgical margin without harming healthy tissue, resulting in reduced local recurrence, improved overall survival, and the potential eradication of post-surgery residual cancer cells.
 

• Furthermore, continual research and technological advancements have enhanced the efficiency and versatility of cold plasma. Developments in equipment, processes, and precision control have improved its practicality and effectiveness in various applications.
   
• Therefore, these advancements, such as portable devices and a better understanding of material interactions, are fueling the adoption of cold plasma across multiple industries, with healthcare benefiting significantly.
   

Cold Plasma Market Analysis

The market by pressure is categorized into atmospheric pressure cold plasma, and low-pressure cold plasma. The atmospheric pressure cold plasma (APCP) segment garnered USD 1.5 billion revenue size in the year 2022. The dominance of the segment can be attributed to its versatile, non-thermal, and practical nature.

• Moreover, operating at atmospheric pressure, cold plasma finds widespread applications in healthcare, electronics, and manufacturing. Its non-thermal attributes allow safe and effective sterilization without heat damage, making it crucial in healthcare.
   
• APCP's advancements in wound healing and environmental applications, along with ongoing research, have solidified its position.
   

Therefore, its ability to offer innovative treatment options and sustainable solutions has driven its market leadership.
 

Based on application, the cold plasma market is segmented into wound healing, cancer treatment, dentistry, blood coagulations, and other applications. The wound healing segment dominated the market and accounted for over 35% business share in the year 2022. High segment growth is driven by its capacity to accelerate tissue regeneration and heal wounds effectively without causing heat damage.
 

• The non-thermal attribute of cold plasma makes it ideal for various wound types. Moreover, its disinfection capabilities reduce infection risks, enhancing patient outcomes. With a growing aging population base, the demand for advanced wound healing solutions is on the rise, further propelling the segment's prominence.
   

The cold plasma market by end-use is categorized into hospitals, dental clinics, research and academic institutions, and other end-users. The hospitals segment garnered USD 786 million revenue size in the year 2022. The segment's dominance is driven by its increased usage of infection control supplies, reducing the risk of hospital-acquired infections (HAIs), among others.
 

• Cold plasma technology finds extensive applications in hospitals for sterilization, wound healing, and cancer treatment, addressing critical medical needs.
   
• Moreover, hospitals also facilitate research and development, compliance with healthcare regulations, and serve as influential early adopters, setting the stage for market growth by validating the technology's effectiveness and safety in various medical applications.
   

U.S. cold plasma market accounted for USD 679 million revenue size in 2022 and is predicted to witness substantial market growth over the analysis timeline.
 

• U.S. claims its dominant position in this market through its robust healthcare infrastructure, thriving pharmaceutical and medical device sectors, a well-established R&D ecosystem, stringent regulatory standards, and substantial healthcare expenditure. These factors collectively promote the widespread adoption of cold plasma technology across various medical applications.
   
• Moreover, U.S. based companies led in developing and commercializing cold plasma, setting global benchmark, and influencing industry trends. The nation's influential role in shaping global healthcare standards further accelerated the growth of the global market.
   

Cold Plasma Market Share

The cold plasma industry is consolidated, with major players such as Adtec Healthcare, and few others dominating the market. These companies focus on ongoing product innovation, geographical expansion, and partnerships to secure substantial market share. For instance, in September 2023, Adtec Healthcare's Steriplas cold plasma device became the first of its kind in Taiwan, with an exclusive partnership with SG Biomedical enabling a strategic entry into the Taiwan healthcare market, projected to boost revenue of the company through this innovative medical technology catering to local needs.
 

Some of the eminent market participants operating in the cold plasma industry include:

• Adtec Healthcare
• Terraplasma Medical
• APJeT, Inc.
• Europlasma
• P2i
• Relyon Plasma
• Tantec A/S
• ColdPlasmatech
• U.S. Medical Innovations (USMI), LLC
• Apyx Medical
• Neoplas Tools GmbH
• Adtec RF
   

Cold Plasma Industry News:

• In August 2023, the Jerome Canady Research Institute (JCRI) and U.S. Medical Innovations (USMI) achieved success in an FDA phase 1 clinical trial by utilizing Canady Helios Cold Plasma (CHCP) alongside tumor resection. This approach selectively eliminated cancer cells at the surgical margin without harming healthy tissue, resulting in reduced local recurrence, improved overall survival, and the potential eradication of post-surgery residual cancer cells. This achievement addressed a critical unmet need in cancer treatment, potentially boosting demand for USMI's technology and driving market expansion.
   
• In April 2020, Relyon plasma GmbH launched the Piezobrush PZ3, an atmospheric plasma system designed for laboratories and small-scale assembly. The device employes Piezoelectric Direct Discharge technology to create cold active plasma with low power consumption (18 W). This addition to the product portfolio increased the company's revenue.
   

Cold plasma market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Pressure, 2018 – 2032 (USD Million)

• Atmospheric pressure cold plasma
• Low-pressure cold plasma

By Application, 2018 – 2032 (USD Million)

• Wound healing
• Cancer treatment
• Dentistry
• Blood coagulations
• Other applications

By End-use, 2018 – 2032 (USD Million)

• Hospitals
• Dental clinics
• Research and academic institutions
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East & Africa